List of Excipients in Branded Drug TARKA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	ALCOHOL
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	CELLULOSE, MICROCRYSTALLINE
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	DOCUSATE SODIUM
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	FERRIC OXIDE RED
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	HYDROXYPROPYL CELLULOSE
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	HYPROMELLOSE
AbbVie Inc	TARKA	trandolapril and verapamil hydrochloride	0074-3287	LACTOSE MONOHYDRATE

TARKA Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

TARKA is a fixed-dose combination of trandolapril, an angiotensin-converting enzyme inhibitor, and extended-release verapamil hydrochloride, a calcium-channel blocker. Its commercial value lies in the controlled-release delivery system and combination-product convenience rather than in a remaining period of meaningful regulatory exclusivity. The strongest opportunities are generic or authorized-generic substitution, reformulation through a 505(b)(2) pathway, regional supply, and differentiated extended-release products with improved food-effect, alcohol-dose-dumping, or swallowability profiles.

What is TARKA and how is it formulated?

TARKA contains trandolapril and verapamil hydrochloride in four marketed strengths:

Strength	Trandolapril	Verapamil hydrochloride
TARKA 1/240	1 mg	240 mg
TARKA 2/180	2 mg	180 mg
TARKA 2/240	2 mg	240 mg
TARKA 4/240	4 mg	240 mg

The product is an extended-release tablet intended for once-daily administration. Trandolapril is absorbed as a prodrug and converted to trandolaprilat. Verapamil is delivered through a controlled-release system designed to reduce peak-to-trough exposure compared with immediate-release dosing. The product label instructs patients to swallow the tablet whole and not crush or chew it, confirming that release control is a core product attribute rather than a secondary manufacturing detail.[1]

TARKA’s dosage form creates two formulation problems:

1. Trandolapril and verapamil have different dose requirements and pharmacokinetic behavior.
2. The tablet must preserve controlled release for a high-dose verapamil load while maintaining acceptable release of the low-dose trandolapril component.

The excipient system therefore must provide matrix control, content uniformity, mechanical strength, chemical stability, and reproducible dissolution across four strengths.

What excipients are used in TARKA?

The FDA labeling record identifies inactive ingredients used in the TARKA tablet and coating system. Public product information identifies excipient classes including lactose, microcrystalline cellulose, hypromellose, povidone, magnesium stearate, colloidal silicon dioxide, talc, titanium dioxide, polyethylene glycol and colorants, although the exact composition may vary by strength, manufacturing site, or labeling revision.[1,2]

Excipient class	Likely functional role in TARKA
Lactose	Diluent and tablet-mass contributor
Microcrystalline cellulose	Filler, compressibility aid and structural support
Hypromellose	Hydrophilic release-controlling polymer
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Talc	Processing aid and coating component
Titanium dioxide	Opacifier and coating pigment
Polyethylene glycol	Film-coating plasticizer
Iron oxides or other colorants	Strength identification and product differentiation

The commercially important excipient is the release-controlling polymer system, particularly hypromellose or a comparable hydrophilic matrix former. The matrix hydrates after administration, forms a gel barrier and regulates diffusion and erosion. Polymer viscosity grade, particle size, substitution level, compression force and tablet porosity can materially change the dissolution profile.

The inactive ingredients should not be treated as interchangeable on a simple qualitative basis. A generic manufacturer can match the listed excipient classes yet fail to reproduce the reference-product release profile if polymer grade, granulation process or coating permeability differs.

What is the excipient strategy behind TARKA?

TARKA’s excipient strategy is based on a controlled-release matrix with conventional tablet-processing support. The product does not depend on a complex device, osmotic pump or enteric capsule. That makes it technically accessible to generic development, but it shifts risk into dissolution control and bioequivalence.

Release-controlling matrix

Hypromellose or another hydrophilic polymer provides the principal release-control function. The polymer must withstand compression while hydrating consistently in gastrointestinal fluid. Excessive polymer loading can produce slow release and incomplete exposure. Insufficient polymer loading can cause rapid release, high verapamil peaks and failure of the reference dissolution profile.

High-dose verapamil accommodation

The 180 mg and 240 mg verapamil strengths require substantial drug loading. The excipient system must preserve tablet hardness without creating a dense core that releases drug too slowly. Microcrystalline cellulose, lactose and binder levels affect porosity, tensile strength and fluid penetration.

Low-dose trandolapril uniformity

Trandolapril is present at only 1 mg, 2 mg or 4 mg. Low-dose content uniformity is a central manufacturing risk. Granulation, premixing, particle-size control and segregation management can have more commercial importance than the choice between common diluents.

Film coating

The film coat can protect the tablet, improve swallowability, identify strengths and affect moisture ingress. A coating that is too dense can alter dissolution if it materially delays water penetration. A coating that is too porous can increase moisture sensitivity and reduce physical stability.

Lubrication control

Magnesium stearate is standard for tableting but can slow dissolution when overmixed or used at excessive concentration. Lubrication time, rather than merely lubricant percentage, should be controlled during scale-up.

What formulation patents protect TARKA?

TARKA’s original commercial protection was likely directed to the combination, dosage form, controlled-release arrangement and therapeutic use rather than to broad ownership of common excipients. The original U.S. NDA was approved in 1996.[3]

The commercially relevant intellectual-property categories are:

IP category	Relevance to TARKA
Fixed-dose combination	Covers or supports combined use of trandolapril and verapamil
Extended-release dosage form	Protects controlled delivery of verapamil in combination with trandolapril
Dose ratios and strengths	Supports the marketed 1/240, 2/180, 2/240 and 4/240 products
Method of treatment	Covers treatment of hypertension using the combination
Manufacturing process	May address granulation, compression, coating or release control
Stability formulation	May protect moisture control, packaging or impurity reduction

The core formulation value is unlikely to arise from any single conventional excipient. Common excipients such as lactose, microcrystalline cellulose, hypromellose and magnesium stearate generally provide limited standalone patent protection. The defensible position, if any, would be in the specific composition, ratios, process parameters, dissolution profile or clinical use.

The original patents associated with TARKA should be checked against the current FDA Orange Book, USPTO records, and any relevant terminal disclaimers before a launch or freedom-to-operate decision. Patent status cannot be inferred from the existence of the NDA, and historical product patents may have expired or been delisted.

When did TARKA lose exclusivity?

TARKA’s original FDA approval occurred in 1996, so its five-year New Chemical Entity exclusivity period expired long ago. Any pediatric, orphan, qualified infectious-disease or other statutory exclusivity would not be expected to remain relevant to this antihypertensive product.

The key commercial conclusion is that TARKA is a mature small-molecule combination product. Its main barriers are likely to be:

• Bioequivalence against an extended-release reference product.
• Availability and quality of reference samples.
• Reproducible dissolution across strengths.
• Low-dose trandolapril content uniformity.
• Manufacturing economics at modest market volume.
• Physician and payer preference for separate generic components.

What is the Orange Book status of TARKA?

The Orange Book is the controlling source for current U.S. reference-listing, patent-listing and exclusivity information. TARKA’s regulatory significance is its NDA and reference-product history, not an expected remaining period of branded exclusivity.

An applicant evaluating TARKA should review:

1. Whether the NDA remains listed as approved.
2. Whether any TARKA strength remains commercially marketed.
3. Whether the product is designated as the reference listed drug for an ANDA.
4. Whether patents are listed under the NDA.
5. Whether any patents have expired, been delisted or remain subject to certification.
6. Whether FDA has identified a therapeutically equivalent product.

Because TARKA combines an ACE inhibitor and calcium-channel blocker, an applicant may also evaluate whether the regulatory pathway is more efficient through an ANDA referencing TARKA or through a 505(b)(2) application based on a modified release system.

Are Paragraph IV challenges relevant to TARKA?

Paragraph IV litigation risk is likely lower than for a recently launched branded drug because TARKA is an older product. If current Orange Book-listed patents exist, an ANDA applicant would need to address each listed patent through Paragraph III or Paragraph IV certification, depending on the intended launch timing.

A Paragraph IV strategy would be commercially relevant only if:

• The patent remains unexpired.
• The patent is listed against the relevant NDA.
• The proposed product differs sufficiently to create a non-infringement or invalidity position.
• The expected market supports litigation and launch risk.

For an old fixed-dose combination, a patent challenge may be less attractive than a design-around using a different polymer system, a different coating architecture or a separate-component commercial strategy. A Paragraph IV assessment requires the current Orange Book patent list and live patent claims. Historic patent references alone do not establish present litigation risk.

What generic entry risks exist for TARKA?

The most significant generic risks are technical rather than patent-based.

Bioequivalence risk

An applicant must demonstrate comparable exposure for both active ingredients. Verapamil’s extended-release profile can be sensitive to formulation changes, food effects and gastrointestinal transit. Trandolapril adds a low-dose analyte problem and requires reliable measurement of relevant active moieties.

Dissolution risk

A product can match pharmacokinetic averages while showing a materially different dissolution curve. FDA review may focus on multiple media, agitation conditions, dose strengths and release stages. The development program should use discriminating dissolution methods rather than a single routine assay.

Alcohol-induced dose dumping

Controlled-release systems must be evaluated for accelerated release in the presence of ethanol. A hydrophilic matrix can behave differently under alcohol exposure depending on polymer hydration and tablet structure. A formulation that passes standard dissolution but releases verapamil rapidly in alcohol may create a regulatory obstacle.

Food-effect risk

Food may change gastric residence time, fluid availability and polymer hydration. The formulation should be evaluated under fed and fasted conditions, particularly because verapamil exposure and tolerability are clinically relevant.

Scale-up risk

Changes in blending time, granulation endpoint, compression force or coating weight can alter release. Process analytical technology and in-process controls can reduce this risk, but the critical process parameters must be identified early.

What commercial opportunities exist for TARKA excipients?

Generic TARKA tablets

The most direct opportunity is supply of a bioequivalent generic tablet. The product uses broadly available excipient classes, so raw-material access is unlikely to be the main barrier. The value is in process know-how, dissolution matching and regulatory execution.

Authorized generic

An authorized generic could use the branded product’s established formulation and manufacturing network. This approach may reduce formulation risk and support institutional contracts, although commercial value depends on whether the product remains actively marketed.

505(b)(2) reformulation

A 505(b)(2) product could use:

• A lower-pill-burden tablet.
• An improved once-daily release profile.
• A modified polymer matrix.
• A capsule or multiparticulate system.
• A formulation with improved swallowability.
• A product designed to reduce food-effect variability.

This route could create new formulation patent opportunities, but it would require a clear clinical or pharmacokinetic rationale. A minor excipient substitution without a meaningful product advantage would have limited commercial protection.

Separate-component substitution

Many physicians can prescribe trandolapril and extended-release verapamil separately. A company can commercialize the components independently and compete for the same treatment regimen without reproducing the fixed-dose tablet. This strategy reduces combination-product development risk but loses the adherence and convenience advantages of TARKA.

Regional and institutional supply

Mature antihypertensive combinations can have value in markets where fixed-dose products are included in formularies, government tenders or hospital procurement programs. Contract manufacturing and secondary sourcing may be more attractive than a U.S. branded launch.

How does TARKA compare with separate trandolapril and verapamil products?

Factor	TARKA	Separate products
Pill burden	One tablet	Two dosage units
Dose flexibility	Limited to marketed ratios	Broad
Adherence	Potentially improved	More complex
Development burden	Requires dual-ingredient bioequivalence	Ingredient-specific
Formulation complexity	High because of controlled release and low-dose combination	Lower per product
Commercial differentiation	Convenience and fixed ratio	Flexibility and availability
Substitution risk	Can be replaced by two generics	Can replace TARKA regimen
Patent opportunity	Combination and release system	Ingredient or formulation-specific

TARKA’s commercial advantage is convenience. Its commercial weakness is the fixed ratio. Patients requiring a different ACE-inhibitor or verapamil dose may be better served by separate products.

Does TARKA face biosimilar competition?

No. TARKA is a small-molecule drug product, not a biologic. It is subject to generic-drug pathways, including ANDA review, rather than biosimilar approval under the Public Health Service Act. The relevant competitors are generic fixed-dose combinations, separate trandolapril and verapamil products, and other antihypertensive combinations.

What manufacturing and IP barriers matter most?

The practical barriers are formulation replication and regulatory evidence.

A developer should prioritize:

1. Particle-size and blend-uniformity control for low-dose trandolapril.
2. Polymer grade and loading optimization.
3. Compression-force control.
4. Multi-strength dissolution matching.
5. Fed and fasted pharmacokinetic performance.
6. Ethanol challenge testing.
7. Moisture-protective packaging.
8. Supplier qualification for pharmaceutical-grade polymers and lubricants.
9. Stability-indicating impurity methods.
10. Freedom-to-operate review of any modified-release claims.

Packaging may also have commercial importance. Moisture-barrier blistering or high-density polyethylene bottles with desiccant can protect release performance and impurity limits. The selected packaging system should be developed with the tablet formulation rather than added after scale-up.

What patent litigation or settlement activity affects TARKA?

No major current TARKA patent litigation or settlement can be identified from the core historical regulatory record. Given the age of the product, any present litigation assessment should focus on later generic applications, formulation patents, manufacturing patents or ownership disputes rather than the original approval.

A settlement involving a generic applicant would matter only if it controlled market entry, authorized-generic rights or supply arrangements. The absence of a known high-profile settlement does not establish that no historical ANDA litigation occurred.

Key Takeaways

• TARKA is a trandolapril/verapamil hydrochloride extended-release fixed-dose tablet.
• Its excipient strategy depends on a hydrophilic controlled-release matrix, conventional tablet fillers and a protective film coat.
• The main formulation challenge is combining high-dose extended-release verapamil with low-dose trandolapril.
• The product’s original 1996 approval means branded regulatory exclusivity is expired.
• Generic development risk is concentrated in dissolution, food effect, alcohol dose dumping and content uniformity.
• TARKA is not subject to biosimilar competition.
• The strongest commercial opportunities are generic substitution, authorized generic supply, 505(b)(2) reformulation and regional institutional sales.
• Common excipients provide limited standalone patent protection. Any durable IP position would likely require a specific release profile, composition, process or clinical use.
• Current Orange Book and patent-register review is required before relying on any patent expiration or Paragraph IV conclusion.

FAQs

Can TARKA be reformulated with a different polymer?

Yes, provided the revised product meets applicable bioequivalence, dissolution, stability and safety requirements. A different polymer may create a 505(b)(2) opportunity but also increases regulatory and formulation risk.

Is a TARKA generic required to use the same excipients?

No. An ANDA generally does not require identical inactive ingredients, but the proposed excipients must be acceptable for the dosage form and must support equivalent performance.

Does TARKA have an orphan-drug exclusivity period?

No orphan-drug exclusivity is associated with this antihypertensive combination in the ordinary regulatory record.

Could a multiparticulate TARKA product obtain new patents?

Potentially. A multiparticulate product could support patents directed to pellet composition, polymer layering, release kinetics, dose ratios, capsule architecture or food-effect control. Patentability would depend on novelty, non-obviousness and claim scope.

Is separate generic trandolapril plus verapamil a direct commercial substitute for TARKA?

Yes, therapeutically it can substitute for the fixed-dose regimen when the patient receives equivalent active ingredients and appropriate dosing. The tradeoff is higher pill burden and greater dose flexibility.

References

1. U.S. Food and Drug Administration. (n.d.). TARKA (trandolapril and verapamil hydrochloride) extended-release tablets prescribing information. Drugs@FDA.

2. National Library of Medicine. (n.d.). Tarka: Trandolapril and verapamil hydrochloride tablet, extended release. DailyMed.

3. U.S. Food and Drug Administration. (1996). New drug application 020401: TARKA. Drugs@FDA.

4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. U.S. Food and Drug Administration. (2015). M9 biopharmaceutics classification system-based biowaivers: Guidance for industry. FDA.